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Investigation of the genetic alterations underlying squamous cell
carcinoma of the head and neck (SCCHN) has recently allowed
identification of a number of key genes frequently altered during
disease progression. Many of these studies have concentrated on the
role of oncogenes and tumour suppressor genes in the disease. Thus,
oncogenes c-myc (Field et al, 1989), EGFR (Ke et al, 1998), HER-
2/neu (Xia et al, 1997) and cyclin D1 (Michalides et al, 1995), and
tumour suppressor genes p53 (Somers et al, 1992) and p16 (Reed et
al, 1996; Lang et al, 1998), demonstrate disease-specific alterations
during genesis of SCCHN. However, a number of studies have
implicated additional chromosomal loci in the disease, suggesting
the existence of additional unidentified genes, which may be targets
for inactivation during SCCHN development (Nawroz et al, 1994;
Califano et al, 1996; Loughran et al, 1997; Bockmuhl et al, 1998). 
In this study, we have performed Representational Difference
Analysis (RDA) (Diatchenko et al, 1996) in order to identify novel
genes expressed in normal epithelium but absent from SCC. This
study has allowed isolation of a differentially expressed novel
gene named DESC1. DESC1 possesses strong identity to members
of the serine protease superfamily, and shows highest degree
of homology with Human Airway Trypsin-like protease (HAT;
Yamaoka et al, 1998). 
MATERIALS AND METHODS 
RNA isolation 
Normal human keratinocytes (NHEK-Neo, NHEK-Ad) and prostate
epithelial cells (PrEC) were cultured in keratinocyte growth medium
(KGM) or prostate epithelial cell growth medium (PrEGM)
(Clonetics, San Diego, CA) respectively and exponentially growing
cells harvested. Tissue samples were provided by the Cooperative
Human Tissue Network, funded by the National Cancer Institute.
Total RNA was extracted from cell lines and tissue as previously
described (Gramza et al, 1995). Normal prostate and testes RNA
was obtained from CLONTECH (Palo Alto, CA) and normal skin
RNA from Invitrogen (Carlsbad, CA). Polyadenylated RNA was
selected utilizing an Oligotex kit (Qiagen, Santa Clarita, CA). 
Representational difference analysis and gene cloning 
Representational Difference Analysis (RDA) was performed by
utilizing PCR-Select cDNA subtraction methodologies (CLON-
TECH, Palo Alto, CA) precisely as described in the manu-
facturer’s protocol. PCR amplification products obtained were
cloned directly into mammalian expression vector pCMV-Script
(Stratagene, La Jolla, CA). Additional DESC1 5¢ and 3¢ sequence
not present in CMV-Script clone, was obtained by 5¢ and 3¢ RACE
analysis utilizing both 5¢ and 3¢ RACE systems (Gibco BRL,
Gaithersburg, MD). A full-length DESC1 cDNA clone (pDESC1)
was constructed following contig analysis of sequence obtained
from pCMV-Script, 5¢ and 3¢ RACE clones. pDESC1 was gener-
ated by cloning of the DESC1 RT-PCR amplification product
derived from normal human skin RNA (Invitrogen, Carlsbad,
CA) into TOPO TA cloning vector pcDNA3.1/V5/His-TOPO
(Invitrogen, Carlsbad, CA) utilizing DESC1 primers D11 and
D12, which delimit the known DESC1 sequence. 
Inducible expression and Western analysis of DESC1 
The entire DESC1 cDNA was also cloned into inducible expression
vector pIND TOPO TA. This vector was transiently transfected into
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and retinoid X receptor. Induction of DESC1, linked to a paramyx-
ovirus V5 epitope tag, was accomplished by addition of Ponasterone
A to the cell medium as described in the manufacturer’s protocol
(Invitrogen, Carlsbad, CA). 72 hours post transfection, cell lysates
were prepared, 20 µl lysate run on a 10% NuPAGE gel, and blotted
using an XCell II Blot Module (Invitrogen, Carlsbad, CA). Presence
of the recombinant DESC1 polypeptide was confirmed by
WesternBreeze (Invitrogen, Carlsbad, CA) chemiluminescence
detection, utilizing an antibody to the V5 epitope. 
RT-PCR amplification 
1.0 µg of total RNA was used for first strand cDNA synthesis in a
total volume of 25 µl and reactions otherwise performed according
to manufacturer’s instructions (ProSTAR, Stratagene, La Jolla,
CA). PCR amplification was performed in the presence of 2 units
Taq 2000 DNA polymerase (Stratagene, La Jolla, CA), with reac-
tion conditions: 10 mM Tris-HCl (pH 8.8), 50 mM KCl, 1.5 mM
MgCl2, 0.001% gelatin, 1µM each primer, 200 µM dNTPs, and
where appropriate, 0.25 µl [a32P]dCTP (3000 Ci mmol21) in a
final volume of 25 µl. Separate reactions were performed for each
primer pair with reaction conditions; 96˚C 3 min followed by 94˚C
30 s, 55˚C 30 s, 72˚C 1 min for 31 cycles (HPRT) or 33 cycles
(DESC1) and a final 5 min extension at 72˚C. PCR amplification
of full-length DESC1 was performed utilizing the above cycling
conditions, with an additional 1 min extension time for each cycle,
and using the Advantage HF PCR kit (CLONTECH Laboratories
Inc, Palo Alto, CA). PCR samples were then run through 2%
agarose gels and presence of amplified product and correct
product size verified by ethidium bromide fluorescence in the
presence of 100 bp size markers (Gibco BRL, Gaithersburg, MD).
Where appropriate, PCR products generated were electroblotted
using a Bio-Rad Semi-Dri Electroblotter SD and transferred at
12 V/110 mA for 10 min. The membrane was removed, UV
crosslinked and exposed to BioMax film (Eastman Kodak,
Rochester, NY). Primers utilized in PCR reactions comprise:
hypoxanthine phosphoribosyl transferase (HPRT) primers
HPRT1, 5¢-GTAATGACCAGTCAACAGGGGAC-3¢ and HPRT2,
5¢-CCAGCAAGCTTGCGACCTTGACCA-3¢ and DESC1 primers
D3, 5¢-TCACTGTTCATTATGTGAGATATAATCA-3¢; D4, 5¢-
CACCATTGATTCAAGTCTCTGGCTCAT-3¢;D10,5¢-
CCTGTTCCCTACACAAATGCAGTAC-3¢;  D11, 5¢-TGCATC
AAGCAAACAGTTTATTGAGATC-3¢; D12, 5¢-TGACTTGGAT-
GTAGACCTCGACCTTCAC-3¢ and D18, 5¢-GGAATAGTGAGC-
TCGGGAGATG-3¢. Location of primers on the DESC1 sequence
is shown in Figure 1A. PCR amplification of the HPRT gene was
performed as a control to demonstrate equal loading and to deter-
mine integrity of RNA. Primers were designed by computer
analysis (Oligo 4.0; NBI, Hamel, MN) of available DNA sequence
for each gene and, with the exception of primer set D11, D18, are
intron-spanning precluding PCR amplification of any residual
DNA present in RNA samples. Optimum cycle number for PCR
amplification was pre-determined for each primer set using a
mixture of RT reactions from 10 random normal and tumour
samples (data not shown). This step is necessary to ensure that PCR
amplification remains in the linear range and that production of
PCR product does not plateau. Under reaction conditions used,
quantity of PCR product is therefore directly proportional to the
amount of radioactivity incorporated into the DNA. 
Northern hybridization 
Northern blot containing SCC RNA was generated by electro-
phoresis of 25 µg total RNA on a 1.5% glyoxal agarose gel
according to manufacturer’s instructions (NorthernMax-Gly,
Ambion, Austin Tx). Human Cancer Cell Line Multiple Tissue
Northern Blot, Human Multiple Tissue Northern Blot and Human
Multiple Tissue Northern Blot II were purchased from CLON-
TECH Laboratories Inc (Palo Alto, CA). Human Normal Tissue
Blot III was obtained from Invitrogen (Carlsbad, CA). Blots were
hybridized with [a32P]dCTP-labelled DESC1 cDNA probe span-
ning 581 nucleotides of the DESC1 coding sequence (nucleotides
165–746) (Figure 1A), or control b-actin cDNA (CLONTECH
Laboratories Inc, Palo Alto, CA) using ExpressHyb solution
(CLONTECH Laboratories Inc, Palo Alto, CA), according to
manufacturer’s protocol. Blots were then washed in 0.5 3 SSC,
0.1% SDS for 30 min at RT, followed by 0.1 3 SSC, 0.1% SDS for
1 h at 50˚C with 2 changes of solution and exposed to BioMax
film. 
DNA sequencing 
DNA sequence of DESC1 was determined by cycle sequencing
using a Thermo Sequenase system (Amersham, Cleveland, OH),
followed by electrophoresis using the CastAway sequencing
system (Stratagene, La Jolla, CA) according to manufacturer’s
instructions. 
Chromosomal localization of DESC1
Chromosomal mapping of DESC1 was performed by use of a
Somatic Cell Hybrid Panel (Oncor, Gaithersburg, MD), with
hybridization conditions for DESC1 probe as described above.
Chromosomal mapping of DESC1 was additionally performed
using the Genebridge 4 Radiation Hybrid Panel (Research
Genetics Inc, Huntsville, AL) by PCR amplification using
primers D11 and D18. The chromosomal location of DESC1
was then determined by accessing the Whitheead Institute/MIT
Center for Genome Research radiation hybrid map of the human
genome. 
RESULTS 
Isolation of DESC1 by representational difference
analysis 
Specimens for analysis comprising primary carcinoma, metastatic
node and matched normal tissue were obtained from an individual
who presented with a primary SCC of the tongue which was
metastatic to regional neck nodes. Representational Difference
Analysis (RDA) was performed on mRNA isolated from the
normal oral tissue (buccal mucosa) and from an SCC-positive
metastatic neck node. SCC-positive nodal tissue was chosen in
preference to primary carcinoma, precluding the possibility of
contamination of the carcinoma sample with normal oral epithe-
lium. RDA was performed with carcinoma RNA as driver in the
reaction, allowing selection of genes expressed in normal tissue
but not in tumour tissue. 0.5% of the RDA final reaction was
subject to PCR amplification and PCR products cloned into
mammalian expression vector pCMV-Script. 
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All recombinant clones were screened for inserts by PCR analysis
and positive clones subject to sequence analysis using vector-
specific T3 primers. BLASTN sequence analysis was then
performed, using the public domain GenBank sequence database.
One recombinant clone C35, carrying a 581 bp insert, was shown
to represent a novel sequence, and possesses an open reading
frame spanning the full length of the clone. The putative gene
represented by this clone was designated Differentially Expressed
in Squamous Cell Carcinoma Gene 1 (DESC1). C35 was devoid of
consensus polyadenylation signals. In order to obtain the 3¢ end of
the gene, 3¢ RACE analysis was performed on the remaining
normal tissue mRNA used previously for RDA analysis. Sequence
analysis of 3¢ RACE products allowed identification of two
consensus polyadenylation signal sequences separated by 633 bp
(Fig. 1A) and located at nucleotide positions 802 – 808 and
1441–1446. In order to obtain additional 5¢ sequence, 5¢ RACE
was also performed. A full-length cDNA clone (pDESC1) was
then generated by cloning of the DESC1 RT-PCR amplification
product derived from normal human skin RNA. The resulting full-
length  DESC1 cDNA sequence is 1471 nucleotides in length
(Genbank accession #AF064819) and is represented in Figure 1A.
The DESC1 sequence was used to query the GenBank database.
This analysis demonstrates strong sequence homology between
DESC1 and a recently described serine protease, Human Airway
Trypsin-like Protease (HAT) (Figure 1B). Sequence identity
between the two genes at the amino acid level is 38% overall, and
51% when the serine protease catalytic domain only is compared
(DESC1 residues 191–422). This information suggests that
DESC1 is a novel member of the serine-protease gene family. 
DESC1 contains a predicted open reading frame (ORF)
comprising a minimum of 422 amino acids (Figure 1B) with
putative initiation codon at nucleotide position 56 (based on
sequence comparison with HAT) and termination codon at
nucleotide position 1322. However, it is possible that the ORF
may potentially extend 5¢ of nucleotide 56, since nucleotides
53–55 also encode a methionine residue and since no in-frame
termination codons have been identified upstream of the putative
initiation codon in the gene sequence so-far obtained. That
DESC1 is indeed capable of encoding a polypeptide is demon-
strated in Figure 2. The DESC1 gene was linked to an inducible
expression vector (pIND TOPO TA), and expression induced in a
modified 293 cell line (EcR-293) containing a heterodimeric
ecdysone and retinoid X receptor. In this system, induction of
DESC1 was accomplished via the addition of a synthetic
analogue of ecdysone (Ponasterone A) to EcR-293 cells tran-
siently transfected with recombinant vector DESC1/pIND TOPO
TA. Binding of the heterodimeric receptor, in the presence of
Ponasterone A, to a hybrid response element controlling tran-
scription of DESC1 in the recombinant vector, subsequently
induces  DESC1 expression. The DESC1 polypeptide is produced
as a fusion protein with a carboxy-terminal tagged epitope
(paramyxovirus V5). Western blotting using an anti-V5 antibody
confirms the presence of a 52 kDa polypeptide comprising
DESC1 (47 kDa) and the V5 epitope tag (5 kDa). 
The DESC1 polypeptide possesses four regions of conserved
homology with members of the serine protease gene family which
further suggest that DESC1 is a serine protease. These regions
comprise the 3 domains surrounding the conserved amino acids of
the catalytic triad known to be essential for function of the serine
proteases (Cheah et al, 1990), histidine (residue 231), aspartic acid
(residue 276) and serine (residue 372). The fourth domain
comprises the catalytic cleavage site, cleaving between residues
190 (arginine) and 191 (isoleucine) (Figure 1B). In addition,
DESC1 contains a hydrophobic region spanning residues 18–37
which represents a putative transmembrane domain. Thus DESC1
may, similar to HAT, be a transmembrane-spanning serine protease
possessing an extracellular COOH-terminal catalytic region. 
Expression studies of DESC1
Figure 3 demonstrates that DESC1 is expressed at a high level in
the original normal tissue sample used for RDA analysis, but, in
contrast, is expressed at a very low level in the primary tongue
carcinoma and is absent from the metastatic nodal tissue derived
from the same individual. Residual expression of DESC1 in the
primary carcinoma may however result from low-level contamina-
tion of the tumour tissue with a small amount of surrounding
normal cells. 
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Figure 1 (A) Schematic representation of DESC1. Putative open reading
frame is shown as shaded box. Position of primers used for PCR
amplification is shown as shaded arrow. Location of hybridization probe is
shown as solid arrow. Location of polyadenylation signal is shown as solid
triangle. (B) Derived amino acid sequence for DESC1 and comparison with
serine protease HAT. Identical amino acids are boxed. Residues predicted to
represent conserved amino acids of the catalytic triad (His 231, Asp 276 and
Ser 372) are shown in bold, as are residues 18 (Trp) through 37 (Leu)
representing a putative transmembrane-spanning hydrophobic domain.
Suggested location of catalytic cleavage site is shown as vertical arrow Since DESC1 was isolated from normal buccal mucosa tissue
and not from normal tongue (site of primary carcinoma), it was
especially important to further determine whether DESC1 is
differentially expressed consistently between normal tissue and
carcinoma in patient specimens, other than the parental tissue used
for RDA analysis. Figure 4 shows RT-PCR analysis of expression
of  DESC1 in 10 SCC specimens, and matched normal tissue,
selected from diverse sites in the head and neck region. The results
show lower levels of expression of DESC1 in 9/10 primary carci-
nomas relative to the level of expression in matched normal tissue.
All normal tissue specimens were harvested from clinically
appearing normal tissue located at least 3 cm from the tumour
margin. Pathological evaluation of the normal tissue was
performed. The relative levels of expression of DESC1 in normal
tissue samples also varies between specimens, while the expres-
sion level of control gene HPRT remains constant. 
Since  DESC1 was isolated from normal oral mucosal tissue,
which additionally contains cells of non-epithelial origin, it was
essential to determine whether DESC1 expression was epithelial-
specific. The expression level of DESC1 was therefore determined
in epithelial cell lines and tissue. Figure 5 demonstrates that DESC1
is expressed in normal neonatal (NHEKNeo) and adult (NHEKAd)
keratinocytes, and in normal prostate (PrEC) epithelial cells,
confirming epithelial-specific expression of the gene. Figure 5 also
demonstrates DESC1 expression in human skin and additionally in
prostate tissue, supporting the detection of DESC1 in the epithelial
cell lines. Expression of DESC1 is also seen in testes tissue but at a
lower level. In contrast, no expression of DESC1 was detectable in
COLO320 (colon carcinoma), MCF7 (breast carcinoma), A431
(epidermoid carcinoma), nor in cell lines of haematopoietic origin,
K562 and U937. To date, expression of DESC1 has not been
detected in any cell line of non-epithelial origin. 
To further characterize the tissue-specific expression pattern of
DESC1, Northern analysis was performed on a squamous cell
carcinoma specimen, matched normal oral tissue, and other
diverse human tissue samples and cell lines. The results are shown
in Figure 6 and demonstrate a high degree of tissue specificity of
DESC1 expression. Northern analysis, utilizing total RNA, shows
expression of DESC1 in normal oral, gingival tissue but not in
gingival squamous cell carcinoma from the same patient (Figure
6A). Figure 6A also shows faint, but detectable DESC1 expression
in squamous cell carcinoma cell line SCC4, derived from a tongue
carcinoma, but no expression in SCC25. DESC1 is also detectable
in normal tonsil tissue (Figure 6B) using a total RNA blot. Under
these conditions no significant level of DESC1 expression can be
detected in any other tissue examined including prostate and
testes. Figure 6C demonstrates, however, that when Northern
analysis is performed with a higher degree of sensitivity, utilizing
polyadenylated RNA rather than total RNA, DESC1 expression
can again clearly be detected in prostate and testes. All other
human tissues shown, and additionally heart, brain, placenta, lung,
liver, skeletal muscle and kidney (Human Multiple Tissue
Northern Blot, CLONTECH Laboratories Inc, Palo Alto, CA) (not
shown) do not demonstrate detectable levels of expression of
DESC1 suggesting that this gene is strongly tissue-specific in its
pattern of expression. In addition, expression of DESC1 can be
detected at a very low level in pancreas (data not shown). A panel
of human cancer cell lines (Human Cancer Cell Line Multiple
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Figure 3 DESC1 expression in normal tissue and metastatic neck node
used for RDA analysis and in primary carcinoma from the same patient.
Primers utilized: D10, D11. Size of RT-PCR product, 555 bp 
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Figure 4 RT-PCR analysis of DESC1 expression in SCCHN and matched
normal tissues. Primers utilized: D3, D4. Size of RT-PCR product 149 bp.
Low molecular weight band seen in reverse transcriptase-negative control
lane and some sample lanes represents unincorporated [a32P]dCTP. PHA,
pharynx; TSL, tonsil; FOM, floor of mouth; TON, tongue; EPI, epiglottis; LAR,
larynx 
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Figure 5 Expression of DESC1 in epithelial cell lines and human tissues.
RT-PCR analysis using total RNA derived from human epithelial cell lines
and tissues. Primers utilized, D10 and D11 
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Figure 2 Inducible expression of DESC1 polypeptide. Western blot
showing expression in 293 cells of 52 kd polypeptide consisting of DESC1
(47 kDa) and tagged V5 epitope (5 kDa) after induction with Ponasterone.
Lysates from duplicate flasks are shown Tissue Northern Blot, CLONTECH Laboratories Inc, Palo Alto,
CA), including haematopoietic cells HL-60, K-562, MOLT-4 and
RAJI, colon carcinoma SW480, lung carcinoma A549, melanoma
G361 and HeLa cells also lack detectable expression of DESC1
(data not shown). The results show one predominant transcript of
2.2 kb in normal matched tissue from SCC specimen #252 (Figure
6A), and two other transcripts of 1.6 and 0.6 kb in size, expressed
at a lower level. The 6.0 kb transcript found in prostate mRNA was
not detectable in normal oral tissue specimen #252 (Figure 6A) nor
in RNA isolated from normal tonsil tissue (Figure 6B). However,
the analyses were performed on total RNA only. Whether the
6.0 kb transcript is co-expressed with the other DESC1-specific
transcripts in oral epithelium, or is specific to prostate tissue,
awaits Northern analysis of purified, polyadenylated RNA isolated
from oral epithelial tissue. DESC1 expression in normal tonsil
demonstrates only the 2.2 and 1.6 kb transcripts, which, in
contrast, are expressed at equal intensities. DESC1 expression in
the prostate shows expression of the 2.2 and 1.6 kb transcripts and
an additional transcript of 6.0 kb, but again no detectable expres-
sion of the 0.6 kb transcript. The 1.6 kb transcript alone is
detectable in testes and this may account for the lower level of
DESC1 expression detected in the testes by RT-PCR analysis
(Figure 5). 
DESC1 is located on chromosome 4 
DESC1 was hybridized to a human/rodent somatic cell hybrid
mapping panel. DESC1 hybridizes only to the lane containing
human chromosome 4 and localizes DESC1 to this chromosome
(Figure 7). Further analysis utilizing the Genebridge 4 Rad-
iation Hybrid Mapping Panel localizes DESC1 to the long arm of
chromosome 4, positioned 20.21 cR from marker WI-5548,
and between markers D4S1619 and WI-7844. D4S1619 and WI-
7844 have been mapped by FISH analysis to 4q12 and
4q13 respectively and DESC1 can therefore be placed at 4q12–13
within a region approximately 10Mb in size (personal communica-
tion, Dr Mariano Rocchi, Istituto di Genetica, Italy). 
DISCUSSION 
In this report we describe characterization of DESC1, a novel
human gene encoding a serine protease homologue. DESC1
expression has been detected in all normal specimens of head and
neck-derived epithelium so far examined. In contrast, expression is
reduced or absent in matched specimens of squamous cell
carcinoma obtained from the same group of patients. The expres-
sion level of DESC1 in normal tissue samples varies between
specimens, even when the tissue samples are taken from the same
anatomical site, for example, pharyngeal specimens #54, #69, and
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Figure 6 Expression of DESC1 in multiple human tissues and cell lines.
Northern analysis using total RNA isolated from: (A) SCCHN-derived cell
lines (SCC4 and SCC25), a gingival carcinoma (GIN#252(T)) and matched
normal tissue (GIN#252(N)). Molecular weight markers used: Millennium
Markers (Ambion, Austin, TX). (B) Normal human tissues (Human Normal
Tissue Blot III) and (C) Polyadenylated RNA isolated from normal human
tissues (Human Multiple Tissue Northern Blot II) 
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Figure 7 Chromosomal localization of DESCI. Southern blot
demonstrating hybridization of DESCI cDNA (nucleotides 165–746) to a
Somatic Cell Hybrid Panel. Human chromosome (1–22, X and Y) present in
each hybrid is shown. Lanes 1 and 2 show total human DNA as positive
control. Lanes 3 and 4 comprise total DNA from parental rodent cells used
to produce hybrids
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e#137. To further investigate this observation, the level of expres-
sion of DESC1 in normal oral tissue samples from healthy individ-
uals with no evidence of cancer should be determined. Such
analysis will establish whether the observed variation in expres-
sion of DESC1 in normal epithelial tissue from cancer patients is
representative of premalignant or hyperproliferative changes in
clinically appearing normal epithelium, or simply the result of
normal variation. The lower, but observable expression of DESC1
shown in some primary SCC specimens may represent lower
overall expression in carcinoma tissue or, alternatively, may repre-
sent lack of tumour-specific expression and a degree of contami-
nation of tumour specimens with normal tissue. In support of the
former, a low level of expression of DESC1 can be detected in cell
line SCC4, derived from a tongue carcinoma (Figure 4A). Thus, it
is possible that DESC1 expression may be present in a reduced
amount in many of the SCCHN tumours. It is also possible that
variations in DESC1 expression may, in part, result from differ-
ences in the degree of tumour differentiation. Our preliminary
observations suggest that expression of DESC1 does increase
during enforced differentiation of normal epithelial cells (data not
shown). 
Northern analysis has allowed identification of 4 DESC1 tran-
scripts, 6.0, 2.2, 1.6 and 0.6 kb in length. The additional identi-
fication of an internal consensus polyadenylation signal
(nucleotides 802–807) suggests that the transcriptional organiza-
tion of this locus is complex. The RT-PCR analysis of DESC1
expression shown in Figure 5 utilizes primers D10 and D11,
specific to the 3¢ end of DESC1. This region of the gene is down-
stream from, and therefore does not encompass, the internal
consensus polyadenylation site, although it does contain part of
the conserved catalytic domain of the gene (Figures 1A and 1B).
Since this analysis allows detection of DESC1 expression in
testes, and since, by Northern analysis, testes exhibit only the
smaller 1.6 kb transcript, the data is consistent with identification
of the 1.6 kb RNA as the transcript which encodes the DESC1
polypeptide comprising the serine protease. A second 3¢ RACE
product isolated demonstrates processing of a DESC1 RNA at the
internal polyadelylation site (data not shown). This transcript
terminates at nucleotide 823 and demonstrates that the internal
polyadenylation site is functional. This alternative DESC1 tran-
script has not yet been further investigated, and it is unknown
which transcript it may represent. The transcript cannot encode
the putative DESC1 serine protease and is unlikely to encode an
alternative reading frame, due to the presence of multiple upstream
termination codons in the sequence so far obtained. However,
should this alternative transcript comprise the 2.2 or 6.0 kb RNA,
the remaining 5¢ sequence of this RNA, yet to be determined, may
be sufficient in length to encode another polypeptide. Expression
of the 1.6 and 2.2 kb DESC1 transcripts appear equi-molar in
normal tonsil tissue (Figure 6B), yet, the 2.2 kb transcript
predominates in the matched normal tissue sample from
SCC#252 (Figure 6A). The reason for this difference is not
evident, but further suggests that detailed mapping of the alterna-
tive DESC1 transcripts should be pursued. 
The role of proteases, including serine proteases, in cancer
development is well documented, and demonstrates an associa-
tion between cancer development and activation of proteases
(Liotta and Stetler-Stevenson, 1991). Less well described, is the
inactivation of proteases associated with cancer development.
However, it is interesting that a second, epithelial-specific serine
protease, NES1, has been shown to be down-regulated during
breast cancer development and it has been suggested that this
gene may possess the functional properties of a tumour
suppressor gene (Goyal et al, 1998). The results of our study
suggest that DESC1 may similarly be down-regulated during the
development of SCCHN, although we have no direct evidence to
suggest that DESC1 also possesses the ability to function as a
tumour suppressor. DESC1 is highly expressed in primary,
normal human keratinocytes, epithelial cells previously shown to
be capable of malignant conversion (Rhim et al, 1985).
Functional studies are therefore underway in our laboratory
to determine whether expression of DESC1 is altered during
immortalization and transformation of normal human
keratinocytes and whether enforced expression of DESC1 affects
the growth characteristics of cells already transformed. Although
the precise role of DESC1 in the development of SCCHN is
unknown, the observation of altered DESC1 expression in the
majority of tumours suggests that this gene may represent a useful
marker for squamous cell carcinoma of the head and neck. 
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